Article
Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.
Cell reports. Medicine - 21 May 2024
Alfahel Leenor, Gschwendtberger Thomas, Kozareva Velina, Dumas Laura, Gibbs Rachel, Kertser Alexander, Baruch Kuti, Zaccai Shir, Kahn Joy, Thau-Habermann Nadine, Eggenschwiler Reto, Sterneckert Jared, Hermann Andreas, Sundararaman Niveda, Vaibhav Vineet, Van Eyk Jennifer E, Rafuse Victor F, Fraenkel Ernest, Cantz Tobias, Petri Susanne, Israelson Adrian
Abstract excerpt
Mutations in SOD1 cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron (MN) loss. We previously discovered that macrophage migration inhibitory factor (MIF), whose levels are extremely low in spinal MNs, inhibits mutant SOD1 misfolding and toxicity. In this study, we show that a single peripheral injection of adeno-associated virus (AAV) delivering MIF into adult...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.